1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (7820)
  2. Meeting Abstract (3612)
  3. Review (610)
  4. Editorial (251)
  5. Book Section (189)
  6. Conference Paper (160)
  7. Research Letter (133)
  8. Correspondence (63)
  9. Miscellaneous (62)
  10. Guidelines (30)
  11. Book Whole (6)
Groups
  1. Sloan Kettering Institute Postdocs (12936)
  2. GSK Faculty (6210)
  3. Department of Medicine (4656)
  4. Sloan Kettering Institute Faculty (3490)
  5. Surgery (2557)
  6. Solid Tumor Oncology Division (2525)

More Groups

People
  1. Britta Weigelt (366)
  2. Jorge Reis-Filho (327)
  3. Mithat Gonen (309)
  4. Marc Ladanyi (304)
  5. Joseph Deasy (278)
  6. Michael Berger (278)

More People

Years
  1. 2025 (394)
  2. 2024 (1038)
  3. 2023 (1151)
  4. 2022 (1364)
  5. 2021 (1176)
  6. 2020 (1240)

More Years

Publications
  1. Blood (641)
  2. Cancer Research (542)
  3. Journal of Clinical Oncology (416)
  4. Journal of Nuclear Medicine (261)
  5. Annals of Surgical Oncology (257)
  6. Clinical Cancer Research (235)

More Publications

Publishers
  1. Nature Publishing Group (1308)
  2. Elsevier Inc. (1173)
  3. American Association for Cancer Research (1039)
  4. Springer (818)
  5. Cell Press (719)
  6. American Society of Hematology (697)

More Publishers

Results (12936)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Unraveling the impact of tumor microenvironment on immunotherapy response/resistance in human sarcomatoid clear cell renal cell carcinoma: Insights from a novel mouse model
    Meeting Abstract

    Jiang, H.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Tumor immune microenvironment determinants of response to Lenvatinib and aPD-1 blockade in clear cell renal cell carcinoma
    Meeting Abstract

    Vuong, L.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Circulating leptin and immune-related transcriptomic patterns in clear cell renal cell carcinoma
    Meeting Abstract

    Posada Calderon, L.; Olsson, L.; Kuo, F.; Dawidek, M.; Barbakoff, D.; Ganz, M.; Jiang, H.; Coleman, J. A.; Russo, P.; Furberg, H.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Correction of small bias for clinically relevant CpG sites interrogated by the updated EPICv2/900K methylation array
    Meeting Abstract

    Aldyab, M.; Upadhyayula, N.; Borsu, L.; Nafa, K.; Villafania, L.; Zaidinski, M.; Mullhaney, K.; Bale, T.; Arcila, M.; Ladanyi, M.; more...
    Journal of Molecular Diagnostics (2024)

    Fulltext@MSK | Save
  • Critical roles of type I interferon receptor signaling in myeloid and T cells for virus-induced antitumor responses
    Meeting Abstract

    Baseer Tariq, S.; Wang, Y.; Wang, W.; Salla, B.; Wang, Y.; Liu, S.; Yang, N.; Li, M.; Deng, L.
    Journal of Investigative Dermatology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study
    Meeting Abstract

    Kantor, E.; Bhimani, J.; Gallagher, G. B.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer
    Meeting Abstract

    Gallagher, G. B.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save